ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,769.70
-0.11%
S&P ASX All Technology
3,089.10
-0.16%
Brent Oil
84.695
-0.11%
US Dollar vs AUD
1.49909
-0.14%
Bitcoin
64,880.71
-0.40%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Eledon Pharmaceuticals Inc (ELDN)

  7. Eledon Pharmaceuticals Inc (ELDN) News

ELDN

Eledon Pharmaceuticals (ELDN)

Eledon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ELDN
DateTimeSourceHeadlineSymbolCompany
15/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
15/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
15/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
15/06/202407:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELDNEledon Pharmaceuticals Inc
07/06/202406:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELDNEledon Pharmaceuticals Inc
06/06/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELDNEledon Pharmaceuticals Inc
04/06/202406:01GlobeNewswire Inc.Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationNASDAQ:ELDNEledon Pharmaceuticals Inc
31/05/202406:25Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELDNEledon Pharmaceuticals Inc
31/05/202406:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELDNEledon Pharmaceuticals Inc
25/05/202406:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELDNEledon Pharmaceuticals Inc
15/05/202421:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
14/05/202406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202421:30GlobeNewswire Inc.Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/05/202421:00GlobeNewswire Inc.Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202421:05GlobeNewswire Inc.Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
07/05/202421:00GlobeNewswire Inc.Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementNASDAQ:ELDNEledon Pharmaceuticals Inc
29/03/202407:01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
26/03/202407:56GlobeNewswire Inc.Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionNASDAQ:ELDNEledon Pharmaceuticals Inc
22/03/202401:31GlobeNewswire Inc.Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanNASDAQ:ELDNEledon Pharmaceuticals Inc
15/02/202407:35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ELDNEledon Pharmaceuticals Inc
15/02/202407:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELDNEledon Pharmaceuticals Inc
14/02/202411:01GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
05/01/202408:40GlobeNewswire Inc.Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookNASDAQ:ELDNEledon Pharmaceuticals Inc
05/12/202310:00GlobeNewswire Inc.Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ELDNEledon Pharmaceuticals Inc
30/11/202308:05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
10/11/202309:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELDNEledon Pharmaceuticals Inc
10/11/202308:01GlobeNewswire Inc.Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:ELDNEledon Pharmaceuticals Inc
09/11/202308:05GlobeNewswire Inc.Eledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNASDAQ:ELDNEledon Pharmaceuticals Inc
03/11/202307:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELDNEledon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ELDN

Your Recent History

ASX
WOW
Woolworths
NYSE
KO
Coca Cola
ASX
XAO
Australian SE All Ordina...
NASDAQ
AMZN
Amazon.com
ASX
NAB
National Australia Bank
ASX
FMG
Fortescue
FX
AUDUSD
AUD vs US Dollar
ASX
XJO
S&P ASX 200
NASDAQ
NVDA
NVIDIA
NASDAQ
AAPL
Apple
NYSE
MCD
McDonalds
ASX
TLS
Telstra
ASX
XMM
S&P ASX 300 Metals and M...
FX
GBPAUD
Sterling vs AUD
ASX
XTO
S&P ASX 100
ASX
RIO
Rio Tinto
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved